We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

CANCER SUPPORTIVE CARE DRUGS MARKET ANALYSIS

Cancer Supportive Care Drugs Market, By Drug Class (Nonsteroidal Anti – Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, Granulocyte Colony Stimulating Factor), By Indication(Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukemia, Ovary Cancer, Melanoma Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies), and By Region( North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : Mar 2023
  • Code : CMI2013
  • Pages :175
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market News

Global Cancer Supportive Care Product Market: Key Developments

  • Major players in the market are focused on presenting new portfolios in order to enhance their market share. For instance, in September 2020, Merck a global pharmaceutical, chemical and life science company with a history that began in 1668 and a future shaped by approximately 50,000 employees in 66 countries . Merck announced that more than 30 abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21. The abstracts span the company's clinical program in oncology across several innovative modalities and mechanisms that have the potential to advance treatment across a range of tumor types including biliary tract, lung, and urothelial (bladder) cancers.
  • In 28 December 2022, U.S. Food and Drug Administration (FDA) approved immunotherapy drug atezolizumab (Tecentriq) for the treatment of adults and children 2 years and older with Alveolar soft part sarcoma (ASPS) that has spread to other parts of the body or cannot be removed by surgery.
  • In 21 March 2020, National Cancer Institute has launched the Molecular Characterization Initiative for pediatric tumors. This program offers tumor molecular characterization, also called biomarker testing, to children, adolescents, and young adults with newly diagnosed central nervous system tumors who are being treated at hospitals that are affiliated with the Children’s Oncology Group (COG)

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.